14	Application No.	Annlinant(a)	
	Application No.	Applicant(s)	
Notice of Allowability	09/554,941	ATKINSON ET AL.	
	Examiner	Art Unit	
	Anne R. Kubelik	1638	!
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>response filed 5/18/04.</u>			
2. The allowed claim(s) is/are 18-20, renumbered 1-3.			
3. The drawings filed on are accepted by the Examiner.			
4.			
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal P 6. ☑ Interview Summary Paper No./Mail Dat 7. ☑ Examiner's Amendn 8. ☐ Examiner's Stateme 9. ☐ Other	(PTO-413), e nent/Comment	Y

Art Unit: 1638

## Examiner's Amendment

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Marcia Morton on 8 June 2004.

IN THE CLAIMS:

In claim 18, line 8, the first "and" was replaced with --or--.

In claim 19, line 4, "and" was replaced with --or--.

## IN THE ABSTRACT:

[In one aspect, embodiments of the invention are directed to DNA molecules encoding a fusion protein, wherein the fusion protein comprises at least two anti-pathogenic proteins or protein domains joined by at least one linker peptide. In another aspect, embodiments of the] The invention [are] is directed to a method[s] for improving resistance or tolerance of a plant to a pathogen, wherein the method comprises integrating a DNA molecule encoding a fusion protein comprising at least two anti-pathogenic proteins or protein domains joined by at least one linker peptide, wherein the first anti-pathogenic protein or protein domain comprises Oc-IaD86 or Oc-I and the second anti-pathogenic protein or protein domain comprises CpTI.

Art Unit: 1638

## IN THE TITLE:

## A METHOD OF IMPROVING NEMATODE RESISTANCE IN PLANTS VIA TRANSFORMATION WITH A DNA ENCODING A PROTEINASE INHIBITOR FUSION PROTEIN

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Customer Service at (703) 308-0198.

Anne R. Kubelik, Ph.D. June 8, 2004

ANNE KUBELIK